A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

NCT05904470 PHASE2 COMPLETED Results posted

This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

Details

Lead sponsor	Atea Pharmaceuticals, Inc.
Phase	PHASE2
Status	COMPLETED
Enrolment	275
Start date	Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Chronic Hepatitis C Virus
• Hepatitis C, Chronic
• Hepatitis C
• Hepatic Cirrhosis
• HCV

Interventions

• Bemnifosbuvir
• Ruzasvir

Countries

Pakistan, South Africa, Mauritius, Moldova, South Korea, Philippines, Romania, Canada, United States, Turkey (Türkiye), Brazil, India